E2F1 and breast cancer: In contrast to previous studies in breast cancer [25] which showed robust and uniform subtype-specific patterns of pathway activity, with the above noted exceptions, consistent patterns of oncogenic pathway activity, including MYC, RAS, AKT and RB/E2F1 were not observed across HGSOC subtypes.